Home » Intersect ENT Obtains Reimbursement Designation for Propel Sinus Implant in Germany
Intersect ENT Obtains Reimbursement Designation for Propel Sinus Implant in Germany
InEk, the German Institute for the Hospital Remuneration System, has assigned NUB Status 1 for reimbursement of Intersect ENT’s mometasone furoate implants for 2016, the company announced.
The purpose of the NUB process is to support the introduction of innovative medical products by allowing a limited number of participating hospitals to receive reimbursement.
NUB Status 1 is the highest priority designation available, and was only assigned to a minority of product submissions for 2016, Intersect ENT says. — Jonathon Shacat
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May